ReNetX Bio
Manufacturing · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
157 Church St Fl 19, New Haven, Connecti...Phone Number
(203) 444-6642Website
www.renetx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About ReNetX Bio
ReNetX Bio is developing first-in-class therapeutics to treat injury and damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke, and glaucoma. The company was founded based on innovative technology from Dr. Stephen Strittmatter's work at Yale University to improve neurologic function after CNS injury - creating a significant and completely unmet need estimated at $5B annually. The technology allows neurons to regrow by eliminating factors that inhibit growth and the technology platform has the potential to help restore function in patients who are suffering from spinal cord injuries, stroke and glaucoma.Explore more
ReNetX Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ReNetX Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at ReNetX Bio
Earning: See what the market has to say on ReNetX Bio recently announced quarterly report
Funding: Get notified immidiatlly once ReNetX Bio has new funding data
Check out if ReNetX Bio is spiking on competitors!
ReNetX Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when ReNetX Bio launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check if ReNetX Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if ReNetX Bio had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at ReNetX Bio
Find 3 more new buyers
Compare Similar Companies to ReNetX Bio
Compare insights from companies similar to ReNetX Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ReNetX Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ReNetX Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ReNetX Bio.
ReNetX Bio financials insights
Gather financial insights about ReNetX Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$86K
ReNetX Bio Tech Stack
A closer look at the technologies used by ReNetX Bio
See more technologies
ReNetX Bio News & Media
ReNetX Bio Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of Fusion Protein AXER-204
NEW HAVEN, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate, fusion protein AXER-204. ReNetX Bio, Inc. Announces U.S. FDA Authorization to Proceed for IND Application to Treat Patients with Chronic Spinal Cord Injury
NEW HAVEN, Conn., June 19, 2019 /PRNewswire/ -- ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system disorders, has announced that the U.S. Food and Drug Administration (FDA) has allowed the...ReNetX Bio Closes Series A Funding
ReNetX Bio, Inc., a New Haven-based private biotech company, closed a Series A funding round. The amount of the deal was not disclosed. The round was co-led by Spring Mountain Capital and Connecticut Innovations. The company plans to begin clinical trials on its drug within the year. Founded based on the innovative technology from Dr. […]New Haven-Based ReNetX Bio, Inc. Closes Series A Funding and Expands...
Expansion Enhances City’s Reputation as a Center for Innovation & Jobs (PRWeb May 07, 2018) Read the full story at http://www.prweb.com/releases/2018/05/prweb15467854.htm
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding ReNetX Bio
Sign Up For FreeTo access detailed company insights
ReNetX Bio is developing first-in-class therapeutics to treat injury and damage to the central nervous system (CNS) in conditions such as spinal cord injury (SCI), stroke, and glaucoma. The company was founded based on innovative technology from Dr. Stephen Strittmatter's work at Yale University to improve neurologic function after CNS injury - cre... Read More
